Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tobias Atkin"'
Autor:
Stefano Comai, Nicolas Nunez, Tobias Atkin, Maykel F. Ghabrash, Rita Zakarian, Allan Fielding, Marie Saint-Laurent, Nancy Low, Garrett Sauber, Eugenio Ragazzi, Cecilia J. Hillard, Gabriella Gobbi
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background The endocannabinoid (eCB) system and the serotonin (5-HT) are both implicated in the severity of the depression. 5-HT is synthesized from the amino acid tryptophan (Trp), which is also a precursor for kynurenine (Kyn) whose produc
Externí odkaz:
https://doaj.org/article/7fb56a12fc644014872f5422e0b15c65
Autor:
Tobias Atkin, Panayiotis Tsokas, Todd Charlton Sacktor, Eric M. Schoenfeld, Changchi Hsieh, Jeremy D. Coplan, Ryan Norris, Sasha Fulton, André A. Fenton
Publikováno v:
Learningmemory (Cold Spring Harbor, N.Y.). 28(9)
Protein kinase Mζ (PKMζ) maintains long-term potentiation (LTP) and long-term memory through persistent increases in kinase expression. Early-life adversity is a precursor to adult mood and anxiety disorders, in part, through persistent disruption
Publikováno v:
Journal of Child Psychology and Psychiatry. 58:865-879
Background The management of depressive and mixed symptoms in children and adolescents with bipolar disorder (BD) remains a matter of debate. The goal of this review is, thus, to systematically examine the impact of atypical antipsychotics (AAPs) and
Autor:
Naomi R. Marmorstein, Tobias Atkin, Gabriella Gobbi, Andrea Cipriani, Sorayya Askari, Shouao Wang, Jill Boruff, Nancy E. Mayo, Tomasz Zytynski, Mark A. Ware, Nandini Dendukuri
Importance Cannabis is the most commonly used drug of abuse by adolescents in the world. While the impact of adolescent cannabis use on the development of psychosis has been investigated in depth, little is known about the impact of cannabis use on m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67a336330ce9fb739727faed87fae07a
https://doi.org/10.1001/jamapsychiatry.2018.4500
https://doi.org/10.1001/jamapsychiatry.2018.4500
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99f94252482db792b20b3cf9663f4335
http://hdl.handle.net/11577/3388163
http://hdl.handle.net/11577/3388163